Pharmaceutical · Fiscal year end Sep 30

PRISM BioLab Co.,LTD

206A

株式会社ＰＲＩＳＭ　ＢｉｏＬａｂ

FIGI BBG012FGBKT4206A.T206A JPCorp. no. 6020001095131

Latest half-year results

First half · fiscal year to 2026-09 · filed 2026-05-14

For the first half of the fiscal year to 2026-09: Revenue ¥0.3 billion (+15.8% YoY), Ordinary income ¥-0.6 billion, Net income ¥-0.6 billion.

	This period	Year on year
Revenue	¥253m	+15.8%
Ordinary profit	−¥560m	—
Net profit to owners	−¥603m	—

From the securities report on EDINET, which states no forecast. History via /v1/companies/206A/earnings-releases.

Financials

Japan GAAP · non-consolidated · fiscal year to 2025-09-30

Revenue: ¥677m
Net income: −¥834m
ROE: —
Equity ratio: 87.6%
Dividend / share: —
Employees: 35

Revenue · ¥m

Net income · ¥bn

Fiscal year	Revenue	Net income	Total assets	Net assets	ROE	EPS	Operating CF
2025-09-30	¥677m	−¥834m	¥3,086m	¥2,709m	—	¥-22.82	−¥1,468m
2024-09-30	¥306m	−¥1,050m	¥4,529m	¥3,503m	—	¥-33.53	¥150m
2023-09-30	¥113m	−¥527m	¥1,211m	¥1,148m	—	¥-19.09	−¥514m
2022-09-30	¥554m	¥73m	¥1,740m	¥1,675m	5.3%	¥2.67	¥103m
2021-09-30	¥59m	−¥156m	¥1,510m	¥1,093m	—	¥-1,556.87	—

Indicators

Computed by us from filings · fiscal year to 2025-09-30

Metric	Value	Percentile among listed companies
ROE, %	—	—
Ordinary margin	-1.1048	1.1
Equity ratio, %	87.6	97
Revenue growth	1.2162	99.3
Net income growth	0.2056	56.7
Operating cash flow / assets	-0.4759	0.7

Policy-uncertainty measure1.07 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.

Regulation 2

Ownership activity 0 filer(s) stated they may make proposals in 365 days; 1 new 5% holder(s) in 180 days; net stake change 0.00pt in 90 days; 3.9% held by other listed companies.

Via /v1/companies/206A/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them

Internal control, 2025-12-24: see filing 上記の評価の結果、当事業年度末日時点において、当社の財務報告に係る内部統制は有効であると判断した。 Filing

Segments, votes and tender offers

Stated in EDINET filings

Latest voting result: 2025-12-23 · 取締役3名選任の件 · passed. /v1/companies/206A/voting

Ownership changes

All companies →

2026-10-06

New 5% stake

SBI SECURITIES Co.,Ltd. disclosed a 5.36% stake in PRISM BioLab Co.,LTD (206A), crossing the 5% reporting threshold.

S100Z5Y7Filer profile Original filing (PDF, Japanese)
2026-08-06

Below 5%−5.11pt

SBI SECURITIES Co.,Ltd. cut holdings in PRISM BioLab Co.,LTD (206A) to 0.39% from 5.50%, below the 5% threshold.

S100YTU1Filer profile Original filing (PDF, Japanese)
2026-07-07

New 5% stake

SBI SECURITIES Co.,Ltd. disclosed a 5.50% stake in PRISM BioLab Co.,LTD (206A), crossing the 5% reporting threshold.

S100YOTDFiler profile Original filing (PDF, Japanese)
2025-12-08

Decrease−1.25pt

DBJ Capital Co.,Ltd. reduced holdings in PRISM BioLab Co.,LTD (206A) to 15.24% from 16.49%.

S100X952Filer profile Original filing (PDF, Japanese)
2025-12-08

Decrease−4.59pt

WM PARTNERS Co., Ltd. reduced holdings in PRISM BioLab Co.,LTD (206A) to 6.63% from 11.22%.

S100X956Filer profile Original filing (PDF, Japanese)
2025-12-08

Threshold

Holdings of WM PARTNERS Co., Ltd. in PRISM BioLab Co.,LTD (206A) moved below 10% (11.22% -> 6.63%).

S100X956Filer profile Original filing (PDF, Japanese)
2025-12-08

Below 5%−1.75pt

WM PARTNERS Co., Ltd. cut holdings in PRISM BioLab Co.,LTD (206A) to 4.88% from 6.63%, below the 5% threshold.

S100X95FFiler profile Original filing (PDF, Japanese)
2025-04-01

Below 5%−1.01pt

LifeScience Venture Capital Co.,Ltd cut holdings in PRISM BioLab Co.,LTD (206A) to 4.29% from 5.30%, below the 5% threshold.

S100VIYJFiler profile Original filing (PDF, Japanese)
2025-01-16

Decrease−1.02pt

LifeScience Venture Capital Co.,Ltd reduced holdings in PRISM BioLab Co.,LTD (206A) to 5.30% from 6.32%.

S100V3JIFiler profile Original filing (PDF, Japanese)
2024-12-13

Decrease−0.09pt

individual filer reduced holdings in PRISM BioLab Co.,LTD (206A) to 6.08% from 6.17%.

S100UXNCOriginal filing (PDF, Japanese)

Trades by 5% holders

From the 60-day trade tables in 5% reports

Bought SoldHover a dot for the trade

Holder	Period	Net shares	Net % of shares	Avg. filed price	Range
WMパートナーズ株式会社	2024-05-09 – 2025-12-02	-1,880,700	−5.10pt	¥224.2	¥223–227
DBJキャピタル株式会社	2024-05-09 – 2025-12-02	-195,000	−0.53pt	—	—
ライフサイエンスベンチャーキャピタル株式会社	2024-05-09 – 2025-03-27	-1,269,300	−3.56pt	—	—
individual filer	2024-05-09 – 2024-12-06	0	0.00pt	—	—
DCIパートナーズ株式会社	2024-09-30 – 2024-10-11	-668,900	−1.83pt	¥397.31	¥361–458
individual filer	2024-05-09 – 2024-05-09	0	0.00pt	—	—
Eli Lilly and Company	2024-05-09 – 2024-05-09	0	0.00pt	—	—

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/206A/trades.

5% filings

Large shareholding reports on 206A

Filed	Filer	Stake	Change	Stated purpose
2026-10-06	SBI SECURITIES Co., Ltd.	5.36%	—	—
2026-08-06	SBI SECURITIES Co., Ltd.	0.39%	−5.11pt	—
2026-07-07	SBI SECURITIES Co., Ltd.	5.50%	—	—
2025-12-08	DBJ Capital Co.,Ltd.	15.24%	−1.25pt	pure investment
2025-12-08	WM PARTNERS Co., Ltd.	6.63%	−4.59pt	pure investment
2025-12-08	WM PARTNERS Co., Ltd.	4.88%	−1.75pt	pure investment
2025-04-01	LifeScience Venture Capital Co.,Ltd	4.29%	−1.01pt	pure investment
2025-01-16	LifeScience Venture Capital Co.,Ltd	5.30%	−1.02pt	pure investment
2024-12-13	individual filer	6.08%	−0.09pt	—
2024-12-03	LifeScience Venture Capital Co.,Ltd	6.32%	−1.00pt	pure investment

Cross-shareholdings

From the annual report's status of shareholdings

Listed strategic holdings: — issues
Book value: —
Sold in the year: — — issues
Bought in the year: — — issues
Mutual, both reports: 0
Held by listed cos.: 3

Held by: MEDIPAL HOLDINGS CORPORATION 7459, Eisai Co., Ltd. 4523, MEDINET Co., Ltd. 2370

Purposes, all holdings and mutual flags via /v1/companies/206A/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2025-09-30

Shareholder	Shares	Ratio
DBJキャピタル投資事業有限責任組合	5,829,000	15.83%
ＷＭグロース３号投資事業有限責任組合	3,675,800	9.98%
大和日台バイオベンチャー２号投資事業有限責任組合	3,595,400	9.76%
ＪＰＬＬＣ　ＣＬＩＥＮＴ　ＡＳＳＥＴＳ－ＳＫ　Ｊ(常任代理人　シティバンク、エヌ・エイ東京支店	2,500,000	6.79%
individual holder	1,872,000	5.08%
ｓａｎｔｅｃＨｏｌｄｉｎｇｓ株式会社	1,250,000	3.39%
individual holder	1,170,400	3.17%
大原薬品工業株式会社	1,000,000	2.71%
individual holder	985,000	2.67%
individual holder	935,000	2.54%

Get this as JSON

GET /v1/companies/206A
GET /v1/companies/206A/financials
GET /v1/companies/206A/details
GET /v1/companies/206A/segments
GET /v1/companies/206A/voting
GET /v1/companies/206A/tender-offers
GET /v1/companies/206A/indicators
GET /v1/companies/206A/earnings-releases
GET /v1/events?ticker=206A
GET /v1/companies/206A/trades         
GET /v1/companies/206A/cross-holdings 
GET /v1/companies/206A/brief

Plans from $9 a month · Documentation